Hologic (NASDAQ:HOLX) Releases FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 4.250-4.350 for the period, compared to the consensus EPS estimate of 4.250. The company issued revenue guidance of $4.1 billion-$4.1 billion, compared to the consensus revenue estimate of $4.2 billion. Hologic also updated its Q2 2025 guidance to 1.000-1.030 EPS.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $1.22 during trading on Wednesday, reaching $72.80. The stock had a trading volume of 2,779,067 shares, compared to its average volume of 2,293,025. The firm’s 50 day moving average price is $72.91 and its two-hundred day moving average price is $77.95. Hologic has a one year low of $68.61 and a one year high of $84.67. The stock has a market cap of $16.43 billion, a PE ratio of 21.86, a P/E/G ratio of 2.35 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. On average, research analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HOLX. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday. William Blair reissued an “outperform” rating on shares of Hologic in a report on Monday, January 13th. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Finally, Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.